Active Ingredient History

  • Now
Paliperidone (9-OH-risperidone) is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. Very common adverse effects are: headache, tachycardia, somnolence and insomnia.   NCATS

  • Mol. Mass: 664.91
  • ALogP: 9.11
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$0.6397 - $8492.5112


$1.5750 - $811.8942
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

9-hydroxyrisperidone | invega | invega sustenna | paliperdidone | paliperidone | paliperidone palmitate | r092670 | ro76477 | ro 76477 | ro-76477 | ro92670 | ro-92670 | trevicta | xeplion


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue